A director at Deceuninck NV sold 500,000 shares at 2.500EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Two Directors at UCB SA sold/bought 4,187 shares at 129.920USD. The significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Press release Biocartis Group NV: Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 09 May 2024, 07:00 CEST Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting Mechelen, Belgium, 09 May 2024 – Biocartis Group NV (the "Company") (Euronext Brussels: BCART), announces today that it has decided to postpone the publication of its 2023 Annual Report, in view of the ongoing preparation of the contem...
Persbericht Biocartis Group NV: Biocartis Group NV brengt een update rond de publicatie van haar jaarverslag en de jaarlijkse algemene vergadering BIOCARTIS GROUP NV (Euronext Brussels: BCART) PERSBERICHT - GEREGULEERDE INFORMATIE - 09 mei 2024, 07:00 CEST Biocartis Group NV brengt een update rond de publicatie van haar jaarverslag en de jaarlijkse algemene vergadering Mechelen, België, 09 mei 2024 – Biocartis Group NV (de "Vennootschap") (Euronext Brussels: BCART), kondigt vandaag aan dat zij beslist heeft de publicatie van haar 2023 Jaarverslag uit te stellen, in het licht van de lopen...
Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process Liege, Belgium, 3 May 2024 – 17:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that, after diligent evaluation of , Mithra has selected the offer submitted by Gedeon Richter, which relates to Estetra SRL, Neuralis SA and specific assets held by Mithra R&D SA related to the E4 platform, as a basis for further negotiations and decided to grant exclusivity to Gedeon Richter for the purpose of such negotiation...
Aperam: In-line 1Q24 EBITDA, FCF marked by WC build, 2Q24 guidance below consensus. Ayvens: Taking the brakes off. BAM: Not the best start to the year. bpost: 1Q24 in line with consensus but beat vs INGF, no outlook yet. Brunel International: good set of 1Q24 results – 5% beat on EBIT, comforting trends. B&S Group: Preview - should be a non-event. DEME Group: Preview - should be a non-event. D'Ieteren: Febiac April registrations flat YoY, VW brands up 8.4%. GBL: NAV per share in ...
UCB is entering a next stage of growth as it turns the page on the loss of exclusivity of several of its mature assets. The new chapter will focus strongly on five growth drivers: Bimzelx, Rystiggo, Zilbrysq, Fintepla and Evenity. Jointly, these assets could deliver significant topline growth and margin improvements in the coming years. We have conducted an extensive update of our model to incorporate these new dynamics. Our DCF-based valuation points to a fair value of € 143 per share (previous...
Our Bimzelx launch tracker tool keeps an eye on the ongoing commercialization of Bimzelx in the US by looking at total prescriptions (TRx). Our latest figure for week 22 points to 898 TRx, down 2% versus last week's result, and up 11% on a 4-week rolling basis. Altogether, we see a smooth ramp-up for Bimzelx in its first months since launch.
Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023 Mithra has received binding offers for selected assets, including Estetra SRL, as part of its monetization process. As it stands, the aggregate amount of these offers is insufficient to ensure full repayment of all creditors of Mithra, and, therefore, the offers do not allow to create value for Mithra’s shareholders at the present time.Mithra has requested the suspension of trading of its shares on Euronext Brussels pending continuing negotiations with offering parties.Mithra postpones...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
>Outlook reiterated, inline results, underlying metrics look good - Outlook FY2024 Net result from core activities reiterated at €6.40 and €6.20 DPS.Like-for-like devaluations of -€46m or -0.7% (FY 2023: -2.7%).Healthcare operator performance is improving, with underlying occupancy being strong at >90% for all countries with the exception of Germany (84%) from the data collected.Gross rental income up +2.2% on a like-for-like basis (vs FY2023: +5.5% and...
Basic-Fit: 1Q24 update in line, FY24 outlook in line with consensus at mid-point. bpost: Agreement on Flemish newspaper delivery; risk of provisions largely removed. Cofinimmo: Q1 results in line. Corbion: Tail wags the dog. IMCD: The last hurdle was a harsh clip. Proximus: Strong start to the year, guidance unchanged ahead of Digi arrival. Recticel: Kingspan 1Q24 trading update. Signify: 1Q24 results; revenue decline accelerates. Umicore: Confirms FY 2024 EBITDA guidance range. ...
Cofinimmo reports 1Q24 results in line with our expectations. We were however more negative on potential fair value corrections (-46m,-0.7% vs -99m exp). They were mainly driven by the office segment -1.3% versus -0.7% in HC. In FY24 it expects divestments to be almost net neutral. This was the case in 1Q24 with both 30m divestments and investments. There is another 31m assets held for sale (60/270m confirmed). To date asset sales are lagging a bit but markets are likely to pick up in 2H24. Div...
Gross rental income reached EUR 88.6 m, up 3.4% YoY and +2.2% on an LfL basis. Net income from core activities was EUR 55m, down -3.6% year-on-year.Occupancy remains high at 98.4%.EPRA NTA is stable at EUR 98.31 per share.EPRA net initial yield is stable at 5.5% on average (gross yield at 5.8%).We maintain our Hold rating and leave our TP unchanged at EUR 70.00.
Azelis: Strong margin performance in weak trading results in 3% EBITA beat. BE Semiconductor Industries: 1Q24 results; prolonged downcycle. Coca-Cola Europacific Partners plc: Messy but good. DWS: Record breaking. Flow Traders: Crypto Kings. Fugro: Here we go again. Kinepolis: Weak start to the year, but a bit better than feared. UCB: Changes in the group executive committee. Unilever: Heading in the right direction. Vonovia: Disposal of 4,500 apartments for €700m. Wolters Kl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.